Blirt is proof that the pandemic is not weakening biotech companies. The company from Gdańsk was even forced to increase its production capacity to keep up with the demand. It has invested over PLN 10 million in the development of its laboratories in the Tri-City. The first quarter of 2021 was marked by significant increases in the company’s sales revenues.
Blirt has invested over PLN 10 million in the development of its laboratories in Gdynia and Gdańsk, in particular in the Gdańsk Science and Technology Park. Net revenues from the sale of own products manufactured by the company amounted to approximately PLN 9.3 million in Q1 2021, compared to PLN 1.9 million in Q1 2020, which means an increase of 397% y / y.
Net revenues from the sale of goods the company distributes in Poland, including diagnostic tests for the detection of COVID-19, amounted to approx. PLN 2 million in Q1 2021, compared to PLN 4 million in Q1 2020 ( PLN 3.5 million due to the implementation of important orders), which means a decrease by nearly 50%. y / y
In the area of proprietary products, which are the main source of margin for the company, there was a five-fold increase in sales compared to the state before the early period of the pandemic, i.e. in the first quarter of 2020.
The value of sales in the first quarter of 2021 was lower than in the record-breaking fourth quarter of 2020. This was mainly due to changes in the market situation and changes in the demand structure, which was particularly visible in the first weeks of 2021, said the company.
Blirt S.A. is a Polish biotechnology company established in 1994, headquartered in Gdańsk. It specializes in the production of specialized enzymes and reagents dedicated to use in Life Science. Currently, it is a leading producer of Proteinase K, RNase Inhibitor and other recombinant proteins and enzymes used in molecular biology. The company has been listed on the NewConnect market in Warsaw since 16 March 2011. Shares have surged from 4.5 pln in spring 2020, to the current 21 pln.